Tezepelumab may reduce need for oral corticosteroids in severe asthma

Tezepelumab (Tezspire; AstraZeneca) reduced the need for long-term oral corticosteroid use in a study of adults with severe asthma, researchers have reported in The Lancet Respiratory Medicine. The ‘SUNRISE’ trial tested the monoclonal antibody — given as a monthly subcutaneous injection — in adults with severe asthma who were dependent on medium or high-dose inhaled corticosteroids. […]